Company Filing History:
1 out of 2 
1 out of 7 Years Active: 2024
Title: Estaban Peiró Molina: Innovator in Cardiotoxicity Prediction
Introduction
Estaban Peiró Molina is a notable inventor based in Valencia, Spain. He has made significant contributions to the field of medical research, particularly in predicting cardiotoxicity risk in cancer patients undergoing anthracyclines chemotherapy. His innovative approach has the potential to improve patient outcomes and enhance treatment safety.
Latest Patents
Estaban Peiró Molina holds a patent for a groundbreaking invention titled "Predicting cardiotoxicity risk in cancer patients receiving anthracyclines chemotherapy." This invention refers to an in vitro method for predicting cardiotoxicity risk based on the determination of expression levels of a combination of 10 circulating miRNAs. These miRNAs include miRNA 16-5p, miRNA 22-3p, miRNA 30b-5p/30c-5p, miRNA 92b-3p, miRNA 148a-3p, miRNA-150-5p, miRNA-192-5p, miRNA 215-5p, miRNA 486-3p/486-5p, and miRNA-4732-3p. The invention also identifies this set of miRNAs as biomarkers for predicting cardiotoxicity risk in patients receiving anthracyclines chemotherapy. Furthermore, it contemplates a method for preventing cardiotoxicity by modulating the expression levels of these circulating miRNAs.
Career Highlights
Estaban Peiró Molina has worked with esteemed institutions such as Fundación para la Investigación del Hospital Universitario La Fe de la Comunidad Valenciana and Maastricht University. His work in these organizations has contributed to advancing research in the medical field, particularly in cancer treatment and patient safety.
Collaborations
Some of his notable coworkers include David Hervàs Marin and Ana Santaballa Beltràn. Their collaborative efforts have furthered the research and development of innovative solutions in healthcare.
Conclusion
Estaban Peiró Molina is a distinguished inventor whose work in predicting cardiotoxicity risk represents a significant advancement in cancer treatment. His contributions have the potential to save lives and improve the quality of care for cancer patients.